Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...
Shares of Biogen Inc. BIIB slid 2.21% to $139.39 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.03% to 6,068.50 and the ...
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Bernstein initiated coverage of Biogen Inc (NASDAQ:BIIB) with a “Market-Perform” rating and a price target of $160 as it ...
BofA lowered the firm’s price target on Biogen (BIIB) to $163 from $178 and keeps a Neutral rating on the shares. The firm calls Biogen “one of ...
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
In a report released on February 7, Umer Raffat from Evercore ISI maintained a Buy rating on Biogen (BIIB – Research Report). The company’s ...
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results